Maybe this should be under a new thread but I will have to say that a cell product that deals with inflammatory conditions is pretty powerful, whether or not it is made in America:
https://www.theage.com.au/national/the-silent-killer-why-medical-research-is-fired-up-about-inflammation-20211126-p59cdw.html
The above was actually the best story of the (Sydney Morning Herald companion) Good Weekend magazine of 2022.
The interesting thing is, most people are not aware that inflammation is just a topic that researchers are starting to know more of, as opposed to something that people already know a lot about. In this sense, it is pioneering science if you can come up with product platforms that address multiple inflammatory conditions in multiple organs. Despite what some of us will lament as a bad choice for a first indication, kids’ SR aGVHD approval will open many doors I believe.
Maybe this should be under a new thread but I will have to say...
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.16 |
Change
-0.020(1.70%) |
Mkt cap ! $1.318B | |||
| Open | High | Low | Value | Volume |
| $1.20 | $1.21 | $1.14 | $9.786M | 8.412M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 78042 | $1.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.16 | 189626 | 1 |
View Market Depth
| Last trade - 16.10pm 27/05/2024 (20 minute delay) ? |
|
|||||
|
Last
$1.16 |
Change
-0.020 ( 1.47 %) |
||||
| Open | High | Low | Volume | ||
| $1.21 | $1.21 | $1.14 | 1281085 | ||
| Last updated 15.59pm 27/05/2024 ? | |||||
| MSB (ASX) Chart |